Medicare changes taking effect in January 2026 will require four-week standard care trials before covering advanced wound therapies. The latest service expansion from Kure Care addresses demand for chronic wound care before the critical January 1, 2026 deadline.
Interested parties can learn more at https://curewounds.com
Beginning in January, the Centers for Medicare & Medicaid Services will require wounds to show at least 50 percent reduction in ulcer area during the waiting period before patients can access skin substitutes, cellular therapies, or other proven treatments, according to CMS officials. The policy shift addresses Medicare spending that surged from approximately $252 million in 2019 to over $10 billion in 2024, according to the U.S. Office of Health and Human Services. Medical experts warn that the policy changes, while cost-effective, may create problematic gaps between wound diagnosis and effective intervention for patients with non-healing wounds.
Individuals with diabetic foot ulcers, venous leg ulcers, and pressure injuries should consider seeking evaluation and treatment under current coverage rules, urge experts at Kure Care. Delays linked to the new policies could transform manageable wounds into infections that spread to surrounding tissue or bloodstream for patients with diabetes or compromised immune systems, company officials warn. For individuals with these diagnoses, treatment delays can cause increased infection risk, since their chronic wounds create open pathways for bacterial entry.
The advanced modalities used in Kure Care's regenerative therapies are designed to preserve patients' limbs and function while lowering hospitalization and complication risks. Treatments can accelerate healing by up to 90 percent and reduce recovery time by 60 percent, according to company data.
"After 8 months of traditional treatment with no progress, KureCare's regenerative therapy healed my wound in just 6 weeks," a patient with a diabetic foot ulcer reported. "And Medicare covered everything."
With an extensive history in the industry, Kure Care, a division of Veracor Group LLC, employs specialists who understand both clinical options and administrative challenges during the policy transition. Their team offers guidance through treatment decisions, documentation requirements, and the changing regulatory environment.
For more information, please visit https://curewounds.com/
Kure Care a division of Veracor Group LLC
1150 NW 72ND AVE
TOWER 1 STE 455 #20073
Miami
FL
33126
United States
